Alumis inc (ALMS) - News Archive

A Year of Growth and TransformationAlumis Inc. (NASDAQ: ALMS), a prominent player in the pharmaceutical industry, specifically in Major Pharmaceutical Preparations, recently released its year-end financial results for 2...

Breaking News Date: February 6, 2025 In a groundbreaking announcement today, Alumis and ACELYRIN have officially reaffirmed their commitment to a proposed merger that promises to reshape the landscape of biopharmaceutic...

Alumis and ACELYRIN to Merge: Paving the Way for Transformative Therapies Against Immune-mediated DiseasesIntroductionIn a significant development in the biopharmaceutical sector, Alumis and ACELYRIN have announced plan...

The therapeutic landscape for central nervous system (CNS) disorders is evolving, with advancements in targeted biologics leading to new avenues for treatment. A recent announcement by Alumis regarding the positive resu...

: Systemic Lupus Erythematosus (SLE) poses a considerable challenge in rheumatology due to its heterogeneous nature and the varied response to treatments. Recent data presented at ACR Convergence 2024 by Alumis highligh...

: Recent research presented at the European Academy of Dermatology and Venereology (EADV) congress highlighted promising findings for ESK-001, an oral TYK2 inhibitor, in treating psoriasis. With a focus on a Phase 2 ope...

Alumis Reports Promising Q2 2024 Financial Results and Marks Milestone with ESK-001 Phase 3 ONWARD Clinical Program for Psoriasis Alumis, a biotech leader known for its innovative therapies for chronic inflammatory dise...